Predicted Trait | |
Reported Trait | Colorectal cancer |
Mapped Trait(s) | colorectal cancer (MONDO_0005575) |
Score Construction | |
PGS Name | PRS140_CRC |
Development Method | |
Name | Genome-wide significant variants |
Parameters | NR |
Variants | |
Original Genome Build | NR |
Number of Variants | 140 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000294 |
Citation (link to publication) | Thomas M et al. Am J Hum Genet (2020) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 120,184 individuals (100%) |
PGS Evaluation |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST007856 Europe PMC: 30510241 |
[ ,
52.0 % Male samples |
European | 47 cohorts
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM013009 | PSS009645| Ancestry Not Reported| 8,405 individuals |
PGP000319 | Guo F et al. Clin Gastroenterol Hepatol (2022) |Ext. |
Reported Trait: Risk of colorectal cancer | — | — | Odds ratio (OR, high vs low): 2.61 [2.33, 2.93] | Age, sex, education, body mass index, participation in a health check-up, family history of colorectal cancer, smoking, ever regular use of nonsteroidal anti-inflammatory drugs, and ever regular use of hormone replacement therapy | — |
PPM014884 | PSS009918| European Ancestry| 5,306 individuals |
PGP000350 | Niedermaier T et al. Cancer Prev Res (Phila) (2022) |Ext. |
Reported Trait: Advanced colorectal neoplasia (Ridascreen model) | OR: 1.025 β: 0.02451 |
AUROC: 0.524 [0.499, 0.55] | — | — | — |
PPM014885 | PSS009918| European Ancestry| 5,306 individuals |
PGP000350 | Niedermaier T et al. Cancer Prev Res (Phila) (2022) |Ext. |
Reported Trait: Advanced colorectal neoplasia (FOB Gold model) | OR: 1.036 β: 0.03518 |
AUROC: 0.53 [0.516, 0.545] | — | — | — |
PPM018664 | PSS011059| European Ancestry| 72,791 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.629 [0.613, 0.645] | Hazard Ratio (HR, top 30% of PGS vs. remainder): 1.92 [1.75, 2.23] | age, sex | — |
PPM018665 | PSS011058| East Asian Ancestry| 6,966 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.591 [0.536, 0.625] | — | age, sex | — |
PPM018666 | PSS011060| Hispanic or Latin American Ancestry| 6,660 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.592 [0.531, 0.652] | — | age, sex | — |
PPM018667 | PSS011057| African Ancestry| 5,249 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.581 [0.5, 0.645] | — | age, sex | — |
PPM018668 | PSS011061| European Ancestry| 38,214 individuals |
PGP000294 | Thomas M et al. Am J Hum Genet (2020) |
Reported Trait: Colorectal cancer | — | AUROC: 0.591 | — | age, sex | — |
PPM020729 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Colorectal cancer | — | AUROC: 0.615 [0.529, 0.7] | — | — | — |
PPM020730 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Advanced adenoma | — | AUROC: 0.589 [0.562, 0.616] | — | — | — |
PPM020731 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Non-advanced adenoma | — | AUROC: 0.555 [0.534, 0.576] | — | — | — |
PPM020732 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms | — | AUROC: 0.591 [0.564, 0.617] | — | — | — |
PPM020733 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (50 - 59 years) | — | AUROC: 0.586 [0.544, 0.628] | — | — | — |
PPM020734 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (60 - 79 years) | — | AUROC: 0.597 [0.563, 0.631] | — | — | — |
PPM020735 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (men) | — | AUROC: 0.593 [0.558, 0.629] | — | — | — |
PPM020736 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (women) | — | AUROC: 0.593 [0.553, 0.633] | — | — | — |
PPM020737 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (family history) | — | AUROC: 0.555 [0.471 - 0.639 | — | — | — |
PPM020738 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (non family history) | — | AUROC: 0.599 [0.57, 0.627] | — | — | — |
PPM020739 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (previous colonoscopy) | — | AUROC: 0.607 [0.551, 0.663] | — | — | — |
PPM020740 | PSS011386| Ancestry Not Reported| 3,025 individuals |
PGP000573 | Niedermaier T et al. Cancer Commun (Lond) (2023) |Ext. |
Reported Trait: Any advanced neoplasms (no previous colonoscopy) | — | AUROC: 0.585 [0.555, 0.616] | — | — | — |
PPM020902 | PSS011444| Multi-ancestry (including European)| 4,035 individuals |
PGP000601 | Niedermaier T et al. Clin Transl Gastroenterol (2022) |Ext. |
Reported Trait: Advanced neoplasia (colorectal cancer or advanced adenoma) | — | — | Positive predictive value (PPV, highest PRS tertile): 39.0 [36.0, 42.0] | — | Intermediate (90% specificity) FIT cutoff. |
PPM020901 | PSS011445| Multi-ancestry (including European)| 1,271 individuals |
PGP000601 | Niedermaier T et al. Clin Transl Gastroenterol (2022) |Ext. |
Reported Trait: Advanced neoplasia (colorectal cancer or advanced adenoma) | — | — | Positive predictive value (PPV, highest PRS tertile): 37.0 [31.0, 43.0] | — | Intermediate (90% specificity) FIT cutoff. |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS009645 | — | — | [
|
— | Not reported | — | DACHS | — |
PSS011444 | Participants were classified according to the most advanced finding at colonoscopy (CRC, AA, non-advanced adenoma, other or none of above). Fecal hemoglobin concentrations were measured using Ridascreen Haemoglobin which is based on an enzyme immunoassay (participants recruited until December 2008), and FOB Gold which is based on a latex agglutination assay (participants recruited from December 2008 on). In both groups of participants, fully automated FIT analyses were conducted, blinded with respect to colonoscopy results, using Tecan Freedom Evolyzer (Ridascreen Haemoglobin) and Abbott Architect c8000 (FOB Gold), respectively. | — | [ ,
51.4 % Male samples |
Mean = 61.8 years | European, Not reported | — | BLITZ | — |
PSS011445 | Participants were classified according to the most advanced finding at colonoscopy (CRC, AA, non-advanced adenoma, other or none of above). Fecal hemoglobin concentrations were measured using Ridascreen Haemoglobin which is based on an enzyme immunoassay (participants recruited until December 2008), and FOB Gold which is based on a latex agglutination assay (participants recruited from December 2008 on). In both groups of participants, fully automated FIT analyses were conducted, blinded with respect to colonoscopy results, using Tecan Freedom Evolyzer (Ridascreen Haemoglobin) and Abbott Architect c8000 (FOB Gold), respectively. | — | [ ,
53.5 % Male samples |
Mean = 63.1 years | European, Not reported | — | BLITZ | — |
PSS009918 | — | — | 5,306 individuals, 51.9 % Male samples |
Mean = 62.1 years | European | — | BLITZ | — |
PSS011386 | — | — | 3,025 individuals | — | Not reported | — | BLITZ | — |
PSS011057 | — | — | [ ,
65.5 % Male samples |
Mean = 61.6 years Range = [20.0, 90.0] years |
African American or Afro-Caribbean (African American) |
— | GERA | — |
PSS011058 | — | — | [ ,
42.1 % Male samples |
Mean = 55.8 years Range = [20.0, 90.0] years |
East Asian | — | GERA | — |
PSS011059 | — | — | [ ,
41.6 % Male samples |
Mean = 62.3 years Range = [20.0, 90.0] years |
European | — | GERA | — |
PSS011060 | — | — | [ ,
38.7 % Male samples |
Mean = 55.0 years Range = [20.0, 90.0] years |
Hispanic or Latin American | — | GERA | — |
PSS011061 | The colorectal cancer case subjects were defined as those who had at least two ICD9/10 codes for CRC. Control sub- jects had zero ICD9/10 codes for CRC. Participants with a single ICD9/10 code for CRC were excluded from analysis. | — | [
|
— | European | — | eMERGE | — |